Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
In 2025, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study, “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” The […]
Simmaron’s Solve ME/CFS Catalyst Award-Winning Rapamycin Trial Yields Promising Treatment Findings
Dr. Avik Roy is the chief scientific officer at the Simmaron Research Institute, a non-profit organization dedicated to understanding ME/CFS and related diseases and to treating people with these diseases. […]